Review
Biochemistry & Molecular Biology
Louis Lauwerys, Evelien Smits, Tim Van den Wyngaert, Filipe Elvas
Summary: Cancer immunotherapy utilizes the body's immune system to eliminate tumors, resulting in significant responses for some patients but also potential adverse events. Non-invasive and sensitive molecular imaging techniques are being increasingly used to monitor immune responses and improve treatment efficacy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Chao Li, Chaozhe Han, Shao Duan, Ping Li, Israt S. Alam, Zunyu Xiao
Summary: T lymphocytes are crucial regulators in the adaptive immune response, and inappropriate or imbalanced responses can affect the spatiotemporal dynamics and functional status of T cells. Noninvasive PET imaging offers a highly specific and sensitive method to monitor T-cell dynamics in vivo.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Review
Immunology
Ran Gao, Guo-Ping Shi, Jing Wang
Summary: Regulatory T cells (Tregs) are CD4(+) T cells that can suppress abnormal or excessive immune responses. Targeting Tregs selectively may alleviate their immunosuppressive activities and has shown promising results in preclinical and early-phase clinical trials. Combination therapy has been identified as a better choice than single immunotherapy, radiotherapy, or chemotherapy.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Immunology
Peter Lawrence Smith, Katarzyna Piadel, Angus George Dalgleish
Summary: Cancer vaccination and immunotherapy have revolutionized cancer treatment, but only a minority of patients respond to this treatment and some cancers are resistant to it. CD4(+) and CD8(+) alpha beta T-cells play a crucial role in the anti-tumor immune response, but their function is often compromised in cancer patients.
Article
Oncology
Niloufar Khojandi, Louis Connelly, Alexander Piening, Stella G. Hoft, Michelle Pherson, Maureen J. Donlin, Richard J. DiPaolo, Ryan M. Teague
Summary: The study used single-cell RNA sequencing and T cell receptor sequencing to analyze CD8(+) T cell responses in melanoma patients before and after anti-PD-1 immunotherapy. The results showed that immunotherapy increased transcripts associated with cytolytic effector function and decreased transcripts associated with naive T cells. Additionally, detailed analysis of CD8(+) T cell clones in the blood revealed that responding cells acquired a transcriptional profile consistent with cytolytic effector function.
CANCER IMMUNOLOGY IMMUNOTHERAPY
(2023)
Article
Oncology
S. P. Lau, L. Klaase, M. Vink, J. Dumas, K. Bezemer, A. van Krimpen, R. van der Breggen, L. V. Wismans, M. Doukas, W. de Koning, A. P. Stubbs, D. A. M. Mustafa, H. Vroman, R. Stadhouders, J. B. Nunes, C. Stingl, N. F. C. C. de Miranda, T. M. Luider, S. H. van der Burg, J. G. Aerts, C. H. J. van Eijck
Summary: This study demonstrates the feasibility and safety of using allogeneic lysated dendritic cell vaccine in patients with resected pancreatic ductal adenocarcinoma. The vaccine induces immune reactivity to PDAC expressed antigens and has the potential to prevent disease recurrence and progression.
EUROPEAN JOURNAL OF CANCER
(2022)
Review
Oncology
Shujie Zhou, Mingguo Liu, Fei Ren, Xiangjiao Meng, Jinming Yu
Summary: T cell-based immunotherapies have revolutionized cancer treatment, but limited T-cell infiltration in tumor sites remains a major issue. BiTE therapy, a promising approach using bispecific antibodies to induce tumor lysis, has shown impressive efficacy in B cell malignancies but faces resistance mechanisms such as antigen loss and immune checkpoints upregulation. This highlights the need for modifying antibody constructs and developing combination strategies to enhance efficacy and reduce toxicity, particularly in solid tumors where response to BiTE therapy is poor.
BIOMARKER RESEARCH
(2021)
Article
Chemistry, Multidisciplinary
Seokhyeong Go, Mungyo Jung, Suyoung Lee, Sangjun Moon, Jihye Hong, Cheesue Kim, Yeonseok Chung, Byung-Soo Kim
Summary: A therapeutic cancer nanovaccine has been developed that enhances T cell responses by interacting with both dendritic cells (DCs) and T cells. This nanovaccine, named CCM-MPLA-aCD28, activates tumor-specific CD8+ T cells and exhibits a higher antitumor efficacy compared to nanovaccines that interact with either DCs or T cells.
ADVANCED MATERIALS
(2023)
Article
Gastroenterology & Hepatology
Julie Bonnereau, Tristan Courau, Nicolas Asesio, Delphine Salfati, Fatiha Bouhidel, Helene Corte, Sarah Hamoudi, Nassim Hammoudi, Julie Lavole, Justine Vivier-Chicoteau, Victor Chardiny, Leon Maggiori, Mathieu Blery, Romain Remark, Cecile Bonnafous, Pierre Cattan, Antoine Toubert, Purnima Bhat, Matthieu Allez, Thomas Aparicio, Lionel Le Bourhis
Summary: Objective T cells play a significant role in the immune response against tumors. This study focused on the expression of CD39 on tumor-infiltrating T cells in colorectal cancer (CRC) patients and its potential therapeutic implications. The results showed that CD39 was highly expressed in tumor-infiltrating lymphocytes and its inhibition could promote T cell infiltration and tumor destruction in a coculture model.
Article
Immunology
Farid Ghorbaninezhad, Javad Masoumi, Mohammad Bakhshivand, Amir Baghbanzadeh, Ahad Mokhtarzadeh, Tohid Kazemi, Leili Aghebati-Maleki, Siamak Sandoghchian Shotorbani, Mahdi Jafarlou, Oronzo Brunetti, Mariacarmela Santarpia, Behzad Baradaran, Nicola Silvestris
Summary: DC-based immunotherapy has gained interest in anti-cancer immunotherapies. However, the immunosuppressive mechanisms in the tumor environment, such as inhibitory immune checkpoint molecules, can reduce the efficacy of DC-mediated anti-tumoral immune responses. In this study, we found that blocking CTLA-4 expression on DCs promoted their stimulatory properties and resulted in increased T cell proliferation and cytokine production.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Chemistry, Multidisciplinary
Jihye Hong, Mikyung Kang, Mungyo Jung, Yun Young Lee, Yongbum Cho, Cheesue Kim, Seuk Young Song, Chun Gwon Park, Junsang Doh, Byung-Soo Kim
Summary: While T-cell therapy is a significant breakthrough in cancer immunotherapy, its efficacy against solid tumors is limited due to T-cell exhaustion caused by immunosuppressive mechanisms. T-cell-derived nanovesicles (TCNVs) produced by extrusion through membranes with micro/nanosized pores show promising anti-tumoral activity in the immunosuppressive tumor microenvironment. TCNVs express programmed cell death protein 1 and TGF-beta receptor on their surface, which helps block PD-L1 on cancer cells and scavenge TGF-beta in the TME, preventing T-cell exhaustion and directly killing cancer cells. These findings suggest TCNVs as an effective strategy for cancer immunotherapy to overcome tumor's immunosuppressive mechanisms.
ADVANCED MATERIALS
(2021)
Article
Immunology
Xinlong Zheng, Kan Jiang, Weijin Xiao, Dongqiang Zeng, Wenying Peng, Jing Bai, Xiaohui Chen, Pansong Li, Longfeng Zhang, Xiaobin Zheng, Qian Miao, Haibo Wang, Shiwen Wu, Yiquan Xu, Haipeng Xu, Chao Li, Lifeng Li, Xuan Gao, Suya Zheng, Junhui Li, Deqiang Wang, Zhipeng Zhou, Xuefeng Xia, Shanshan Yang, Yujing Li, Zhaolei Cui, Qiuyu Zhang, Ling Chen, Xiandong Lin, Gen Lin
Summary: The study found that CFR is a newly discovered simple parameter that can be used to identify patients unlikely to benefit from immunotherapy. A higher CFR was strongly associated with improved survival in lung cancer, melanoma, and urothelial cancer immunotherapy cohorts. A higher correlation coefficient was observed between CFR and the ORR following pembrolizumab monotherapy in 20 solid tumor types.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Esther Schoutrop, Thomas Poiret, Ibrahim El-Serafi, Ying Zhao, Rui He, Alina Moter, Johan Henriksson, Moustapha Hassan, Isabelle Magalhaes, Jonas Mattsson
Summary: This study demonstrates the enhanced therapeutic potential of MSLN-CAR T cells expressing a mutated CD3 zeta chain containing a single ITAM for the treatment of ovarian cancer. CAR T cells with calibrated activation potential may improve clinical responses in solid tumors.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Antonella Vardeu, Charlotte Davis, Ian McDonald, Guilherme Stahlberg, Barsha Thapa, Kinga Piotrowska, Margaret A. Marshall, Thomas Evans, Vicky Wheeler, Sarah Sebastian, Katie Anderson
Summary: The use of immunotherapeutic vaccination in prostate cancer is a promising approach. The experimental approach described here uses a well-studied adenovirus-poxvirus heterologous prime-boost regimen, which can induce functional cytotoxic T cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Philippa Meiser, Moritz A. Knolle, Anna Hirschberger, Gustavo P. de Almeida, Felix Bayerl, Sebastian Lacher, Anna-Marie Pedde, Sophie Flommersfeld, Julian Hoenninger, Leonhard Stark, Fabian Stoegbauer, Martina Anton, Markus Wirth, Dirk Wohlleber, Katja Steiger, Veit R. Buchholz, Barbara Wollenberg, Christina E. Zielinski, Rickmer Braren, Daniel Rueckert, Percy A. Knolle, Georgios Kaissis, Jan P. Boettcher
Summary: A study found that the clustering of immune cells within tumors, orchestrated by a specific type of immune cell called cDC1, is a unique feature associated with effective anti-cancer immunity. These clusters promote the activation and expansion of stem-like CD8+ T cells, which play a crucial role in cancer immune control. This finding has important implications for cancer therapy.
Article
Radiology, Nuclear Medicine & Medical Imaging
Zhanhai Tu, Zebin Xiao, Yingyan Zheng, Hongjie Huang, Libin Yang, Dairong Cao
Article
Radiology, Nuclear Medicine & Medical Imaging
Zebin Xiao, Zuohua Tang, Jing Zhang, Guang Yang, Wenjiao Zeng, Jianfeng Luo, Yang Song, Zhongshuai Zhang
JOURNAL OF MAGNETIC RESONANCE IMAGING
(2020)
Article
Medicine, Research & Experimental
Zebin Xiao, Zuohua Tang, Chunquan Zheng, Jianfeng Luo, Keqing Zhao, Zhongshuai Zhang
Article
Radiology, Nuclear Medicine & Medical Imaging
Mengge He, Zuohua Tang, Jinwei Qiang, Zebin Xiao, Zhongshuai Zhang
MAGNETIC RESONANCE IMAGING
(2019)
Article
Pathology
James Monslow, Leslie Todd, John E. Chojnowski, Priya K. Govindaraju, Richard K. Assoian, Ellen Pure
AMERICAN JOURNAL OF PATHOLOGY
(2020)
Article
Radiology, Nuclear Medicine & Medical Imaging
Peng Wang, Zebin Xiao, Zuohua Tang, Jie Wang
EUROPEAN JOURNAL OF RADIOLOGY
(2020)
Review
Immunology
Richard Barrett, Ellen Pure
CURRENT OPINION IN IMMUNOLOGY
(2020)
Review
Biology
Richard Lee Barrett, Ellen Pure
Article
Clinical Neurology
Y. Liu, Z. Ye, J. Hu, Z. Xiao, F. Zhang, X. Yang, W. Chen, Y. Fu, D. Cao
Summary: In spastic paraplegia type 5, microstructural changes were observed in various regions of the spinal cord and brain, with decreased fractional anisotropy, increased mean diffusivity, T1 values, and radial diffusivity values. Additionally, levels of neurofilament light and myelin basic protein were significantly higher in patients with spastic paraplegia type 5 compared to healthy controls.
AMERICAN JOURNAL OF NEURORADIOLOGY
(2022)
Article
Multidisciplinary Sciences
Kelly A. McCorkell, Nipun Jayachandran, Michelle D. Cully, Jacquelyn Freund-Brown, Tiffany Weinkopff, James Monslow, Yinling Hu, Ellen Pure, Bruce D. Freedman, Jorge Alvarez, Michael P. Cancro, Michael J. May
Summary: Global inactivation of IKK-alpha leads to defective lymph node formation and B cell maturation. IKK-alpha in distinct EC-derived compartments is uniquely required to promote B cell homeostasis and LN development, and LEC-intrinsic IKK-alpha is absolutely essential for LN formation.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Oncology
Iris K. Lee, Estela Noguera-Ortega, Zebin Xiao, Leslie Todd, John Scholler, Decheng Song, Maria Liousia, Katheryn Lohith, Kexiang Xu, Kimberly J. Edwards, Michael D. Farwell, Carl H. June, Steven M. Albelda, Ellen Pure, Mark A. Sellmyer
Summary: A noninvasive imaging approach using a PET probe can be used to study the tumor microenvironment and monitor the therapeutic response of FAP-targeted CAR T-cell therapy.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Wenqun Zhong, Zebin Xiao, Zhiyuan Qin, Jingbo Yang, Yi Wen, Ziyan Yu, Yumei Li, Neil C. Sheppard, Serge Y. Fuchs, Xiaowei Xu, Meenhard Herlyn, Carl H. June, Ellen Pure, Wei Guo
Summary: Chimeric antigen receptor (CAR) T-cell therapy has been successful in treating hematologic malignancies, but has limited efficacy against solid tumors. This study found that solid tumors release small extracellular vesicles (sEV) containing tumor antigens and the immune checkpoint protein PD-L1. These sEVs inhibit the proliferation, migration, and function of CAR T cells, acting as an active defense mechanism of solid tumors. Targeting tumor sEVs could optimize CAR T-cell therapy against solid tumors.
Article
Multidisciplinary Sciences
Zebin Xiao, Leslie Todd, Li Huang, Estela Noguera-Ortega, Zhen Lu, Lili Huang, Meghan Kopp, Yue Li, Nimisha Pattada, Wenqun Zhong, Wei Guo, John Scholler, Maria Liousia, Charles-Antoine Assenmacher, Carl H. June, Steven M. Albelda, Ellen Pure
Summary: In preclinical PDAC models, the depletion of FAP-expressing cancer associated fibroblasts with FAP-targeted CAR T cells renders tumors more susceptible to sequential treatment with mesothelin-targeted CAR-T cells. These findings provide a strong rationale for combining tumor stroma- and malignant cell-targeted therapies in clinical trials.
NATURE COMMUNICATIONS
(2023)